IgA Nephropathy, Lymphocyte Homing and IgA Class Switch

Not Applicable

Completed

• Conditions: IgA Nephropathy
• Interventions: Other: blood test

• Registration Number: NCT01775527
• Lead Sponsor: University Hospital, Limoges

Brief Summary

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN.

Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-11
• Study First Submitted: 2013-01-18
• Study First Submitted QC: 2013-01-22
• Study First Posted: 2013-01-25
• Study Start: 2013-02
• Primary Completion: 2014-02
• Study Completion: 2016-06
• Last Update Submitted: 2016-08-19
• Last Update Posted: 2016-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Age > 18 and < 70 years
• IgA nephropathy documented by the kidney biopsy in the six months preceding the inclusion
• Glomerular filtration rate (MDRD formula as simplified) < 90 ml/mn and > 30 ml/mn/1,73 m2
• Consent form signed

Exclusion Criteria

• Patients with cirrhosis or chronic liver disease
• Patients with a history of Crohn's disease or celiac disease
• Patients who received treatment with corticosteroids or affiliates for six months
• Patients who received a live attenuated vaccine during the past 4 weeks
• Patients with a known infection such as HIV, hepatitis B or C
• Patients who presented with a serious infection during the last month
• Breastfeeding women
• Patients not affiliated with a social security scheme
• Under guardianship patient

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
blood test	blood test	-

Primary Outcome Measures

Name	Time	Method
The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization.	30 minutes

Secondary Outcome Measures

Name	Time	Method
The secondary outcome measure is the level of expression of the homing molecules in lymphocytes B IgA memory	30 minutes

Trial Locations

Locations (1)

University Hospital, Limoges; 🇫🇷 Limoges, France